Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease.
However, the current definitions of high-risk prostate cancer include a heterogeneous group …

Clinical reports of limited and treatable cancer metastases, a disease state that exists in a
transitional zone between localized and widespread systemic disease, were noted on …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Purpose: The summary presented herein represents Part II of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of …

Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …

Context The most recent summary of the European Association of Urology (EAU) guidelines
on prostate cancer (PCa) was published in 2011. Objective To present a summary of the …

Background Few data exist regarding the impact on survival of definitive treatment of the
prostate in men diagnosed with metastatic prostate cancer (mPCa). Objective To evaluate …

CONTEXT: Androgen deprivation therapy (ADT) for prostate cancer (PCa) represents one of
the most effective systemic palliative treatments known for solid tumors. Although clinical …

Purpose The detection of lymph-node metastases (N1) with conventional imaging such as
magnetic resonance imaging (MRI) and computed tomography (CT) is inadequate for …

CONTEXT: The optimal management strategy for men with newly diagnosed clinically
localized prostate cancer remains a matter of debate. Numerous series have reported …